Literature DB >> 18278988

The efficacy of acute electroconvulsive therapy in atypical depression.

Mustafa M Husain1, Shawn M McClintock, A John Rush, Rebecca G Knapp, Max Fink, Teresa A Rummans, Keith Rasmussen, Cynthia Claassen, Georgios Petrides, Melanie M Biggs, Martina Mueller, Shirlene Sampson, Samuel H Bailine, Sarah H Lisanby, Charles H Kellner.   

Abstract

OBJECTIVE: This study examined the characteristics and outcomes of patients with major depressive disorder (MDD), with or without atypical features, who were treated with acute bilateral electroconvulsive therapy (ECT).
METHOD: Analyses were conducted with 489 patients who met DSM-IV criteria for MDD. Subjects were identified as typical or atypical on the basis of the Structured Clinical Interview for DSM-IV obtained at baseline prior to ECT. Depression symptom severity was measured by the 24-item Hamilton Rating Scale for Depression (HAM-D(24)) and the 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR(30)). Remission was defined as at least a 60% decrease from baseline in HAM-D(24) score and a total score of 10 or below on the last 2 consecutive HAM-D(24) ratings. The randomized controlled trial was performed from 1997 to 2004.
RESULTS: The typical (N = 453) and atypical (N = 36) groups differed in several sociodemographic and clinical variables including gender (p = .0071), age (p = .0005), treatment resistance (p = .0014), and age at first illness onset (p < .0001) and onset of current episode (p = .0008). Following an acute course of bilateral ECT, a considerable portion of both the typical (67.1%) and the atypical (80.6%) groups reached remission. The atypical group was 2.6 (95% CI = 1.1 to 6.2) times more likely to remit than the typical group after adjustment for age, psychosis, gender, clinical site, and depression severity based on the HAM-D(24).
CONCLUSION: Acute ECT is an efficacious treatment for depressed patients with typical or atypical symptom features. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00000375.

Entities:  

Mesh:

Year:  2008        PMID: 18278988      PMCID: PMC3670137          DOI: 10.4088/jcp.v69n0310

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  37 in total

1.  Antidepressants in clinical practice: limitations of assessment methods and drug response.

Authors:  Sidney H Kennedy; Beata S Eisfeld; Jeffrey H Meyer; R Michael Bagby
Journal:  Hum Psychopharmacol       Date:  2001-01       Impact factor: 1.672

2.  The treatment of anxiety states and atypical depressions by the monoamine oxidase inhibitor drugs.

Authors:  W SARGANT
Journal:  J Neuropsychiatr       Date:  1962-08

3.  Reversed neurovegetative symptoms of depression: a community study of Ontario.

Authors:  R D Levitan; A Lesage; S V Parikh; P Goering; S H Kennedy
Journal:  Am J Psychiatry       Date:  1997-07       Impact factor: 18.112

4.  Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D.

Authors:  Jon S Novick; Jonathan W Stewart; Stephen R Wisniewski; Ian A Cook; Radmila Manev; Andrew A Nierenberg; Jerrold F Rosenbaum; Kathy Shores-Wilson; G K Balasubramani; Melanie M Biggs; Sid Zisook; A John Rush
Journal:  J Clin Psychiatry       Date:  2005-08       Impact factor: 4.384

5.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

6.  Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).

Authors:  Charles H Kellner; Rebecca G Knapp; Georgios Petrides; Teresa A Rummans; Mustafa M Husain; Keith Rasmussen; Martina Mueller; Hilary J Bernstein; Kevin O'Connor; Glenn Smith; Melanie Biggs; Samuel H Bailine; Chitra Malur; Eunsil Yim; Shawn McClintock; Shirlene Sampson; Max Fink
Journal:  Arch Gen Psychiatry       Date:  2006-12

7.  Relief of expressed suicidal intent by ECT: a consortium for research in ECT study.

Authors:  Charles H Kellner; Max Fink; Rebecca Knapp; Georgios Petrides; Mustafa Husain; Teresa Rummans; Martina Mueller; Hilary Bernstein; Keith Rasmussen; Kevin O'connor; Glenn Smith; A John Rush; Melanie Biggs; Shawn McClintock; Samuel Bailine; Chitra Malur
Journal:  Am J Psychiatry       Date:  2005-05       Impact factor: 18.112

8.  Racial disparity in the use of ECT for affective disorders.

Authors:  William R Breakey; Gary J Dunn
Journal:  Am J Psychiatry       Date:  2004-09       Impact factor: 18.112

Review 9.  The validity of atypical depression in DSM-IV.

Authors:  R W Lam; J N Stewart
Journal:  Compr Psychiatry       Date:  1996 Nov-Dec       Impact factor: 3.735

Review 10.  Atypical depression. A valid clinical entity?

Authors:  J W Stewart; P J McGrath; J G Rabkin; F M Quitkin
Journal:  Psychiatr Clin North Am       Date:  1993-09
View more
  6 in total

Review 1.  Neuromodulation for treatment-refractory major depressive disorder.

Authors:  Nir Lipsman; Tejas Sankar; Jonathan Downar; Sidney H Kennedy; Andres M Lozano; Peter Giacobbe
Journal:  CMAJ       Date:  2013-07-29       Impact factor: 8.262

Review 2.  A systematic review of the combined use of electroconvulsive therapy and psychotherapy for depression.

Authors:  Shawn M McClintock; Anna R Brandon; Mustafa M Husain; Robin B Jarrett
Journal:  J ECT       Date:  2011-09       Impact factor: 3.635

Review 3.  Major depressive disorder with psychotic features may lead to misdiagnosis of dementia: a case report and review of the literature.

Authors:  Gerhardt S Wagner; Shawn M McClintock; Peter B Rosenquist; W Vaughn McCall; David A Kahn
Journal:  J Psychiatr Pract       Date:  2011-11       Impact factor: 1.325

Review 4.  The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments.

Authors:  Rodrigo Machado-Vieira; Jacqueline Baumann; Cristina Wheeler-Castillo; David Latov; Ioline D Henter; Giacomo Salvadore; Carlos A Zarate
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-06

Review 5.  Atypical depression: current perspectives.

Authors:  Dorota Łojko; Janusz K Rybakowski
Journal:  Neuropsychiatr Dis Treat       Date:  2017-09-20       Impact factor: 2.570

Review 6.  Depression, mitochondrial bioenergetics, and electroconvulsive therapy: a new approach towards personalized medicine in psychiatric treatment - a short review and current perspective.

Authors:  Alexander Karabatsiakis; Carlos Schönfeldt-Lecuona
Journal:  Transl Psychiatry       Date:  2020-07-09       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.